OmniSeq & LabCorp Launch OmniSeq Advance℠ Assay
New test combines both targeted therapy and immune-oncology biomarkers in a single test with 99% actionability, providing benefits for the treatment of patients and the development of new therapies. ASCO, CHICAGO, ILLINOIS – June 1, 2018 – OmniSeq® , a CAP accredited,...Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
BUFFALO, NEW YORK – April 12, 2018 – OmniSeq® , a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation (TOKYO: 8036, Hitachi High-Tech)’s participation in OmniSeq’s Series B financing...OmniSeq & LabCorp Launch Tumor-Only MSI NGS Assay
BUFFALO, NEW YORK – April 16, 2018 – OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global life sciences company, announced today the commercial launch of OmniSeq MSI NGS, a tumor-only,...OmniSeq Receives CAP Accreditation and Publishes Analytical Validation Paper
Important Achievements Validate OmniSeq’s High Quality Laboratory Practices and Immune Report Card Assay Buffalo, NY – NOVEMBER 9, 2017 – OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it received...OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
Marcia Eisenberg, Chief Scientific Officer of LabCorp Diagnostics, to Join OmniSeq’s Board of Directors BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) — OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that...
Follow Us on Twitter
Immune Report Card®: New Test Matches Patients With Immunotherapies Likely to Work Best | Roswell Park Comprehensive Cancer Center https://t.co/M3a34gfbQG
Proud that OmniSeq has met the rigorous standards needed to become an NCI-MATCH participating lab. Working hard with our colleagues at LabCorp to bring this testing to NCORP sites across the country! https://t.co/qUQTFidjek
OmniSeq Advance "All I Want": https://t.co/NwtMmpXspL via @YouTube
Excellent work being done at UCSD by @Dr_R_Kurzrock to incorporate transcriptomics and clinical trial matching!
"I’m not saying that on the basis of this one trial transcriptomics can become standard of care but the #WINTHER trial definitely suggests transcriptomics should be an important part of additional clinical trials" @Dr_R_Kurzrock
@WIN_Consortium #ASCO18 https://t.co/GSJ7pbu2Cq